Therapeutic modification of the l-arginine-eNOS pathway in cardiovascular diseases
- 1 February 2001
- journal article
- review article
- Published by Elsevier in Atherosclerosis
- Vol. 154 (2) , 255-267
- https://doi.org/10.1016/s0021-9150(00)00736-x
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- l-Arginine Reduces Right Heart Hypertrophy in Hypoxia-Induced Pulmonary HypertensionBiochemical and Biophysical Research Communications, 1999
- Vascular Effects of l-Arginine: Anything beyond a Substrate for the NO-Synthase?Biochemical and Biophysical Research Communications, 1997
- Elevatedl-Arginine/Dimethylarginine Ratio Contributes to Enhanced Systemic NO Production by Dietaryl-Arginine in Hypercholesterolemic RabbitsBiochemical and Biophysical Research Communications, 1996
- Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cellsBiochemical and Biophysical Research Communications, 1991
- Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALBc 3T3 fibroblasts by a cyclic GMP-independent mechanismBiochemical and Biophysical Research Communications, 1990
- L-arginine availability determines the duration of acetylcholine-induced systemic vasodilatation in vivoBiochemical and Biophysical Research Communications, 1989
- L-Arginine causes whereas L-argininosuccinic acid inhibits endothelium-dependent vascular smooth muscle relaxationBiochemical and Biophysical Research Communications, 1989
- Role of the endothelium and arginine peptides on the vaso-motor response of porcine internal mammary arteryLife Sciences, 1989
- Endothelium dependent vascular relaxation by arginine containing polypeptidesBiochemical and Biophysical Research Communications, 1986
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980